IP Library Patent Application 16854757
Patent Application
App. No. 16/854,757

METHODS OF TREATING HYPERTRIGLYCERIDEMIA

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/854,757
Abstract

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

Claims (15)

1 .- 10 . (canceled)

11 . A method of reducing LDL-P in a subject in need thereof, comprising:

determining a baseline LDL-P level associated with the subject; and

administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of ethyl eicosapentaenoate per day.

12 . The method of claim 11 , further comprising, measuring a baseline lipid profile in the subject prior to administering the pharmaceutical composition to the subject.

13 . The method of claim 11 , wherein after administration of the pharmaceutical composition, the subject experiences a reduction in LDL-P of at least about 5% compared to baseline.

14 . The method of claim 13 , wherein the reduction in LDL-P of at least about 5 % compared to baseline is actual % change or median % change.

15 . The method of claim 11 , wherein the subject is administered 2 g to about 4 g of ethyl eicosapentaenoate per day.

16 . The method of claim 11 , wherein the pharmaceutical composition is administered to the subject 1 to 4 times per day.

17 . The method of claim 11 , wherein the ethyl eicosapentaenoate comprises at least about 90%, by weight, of all fatty acids in the pharmaceutical composition.

18 . The method of claim 17 , wherein docosahexaenoic acid and its derivatives comprise no more than about 10%, by weight, of all fatty acids in the pharmaceutical composition.

19 . The method of claim 18 , wherein the pharmaceutical composition is present in a capsule.

20 . The method of claim 16 , wherein the subject is not on concomitant lipid-altering therapy.

21 . The method of claim 20 , wherein the subject is diabetic.

22 . The method of claim 19 , wherein the pharmaceutical composition is packaged in blister packages of about 1 to less than about 20 capsules per sheet.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2020
From: MANKU, MEHAR; OSTERLOH, IAN; WICKER, PIERRE; BRAECKMAN, RENE; SONI, PARESH; AMARIN PHARMA,INC.
To: AMARIN PHARMA, INC.; AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 052460/0582 →